Lymph node regression and survival following neoadjuvant chemotherapy in oesophageal adenocarcinoma. BJS 2018; 105: 1639-1649.
Published: 26th July 2018
Authors: A. R. Davies, D. Myoteri, J. Zylstra, C. R. Baker, W. Wulaningsih, M. Van Hemelrijck et al.
The aim was to define the pathological response in lymph nodes following neoadjuvant chemotherapy for oesophageal adenocarcinoma and to quantify any associated survival benefit.
Lymph nodes retrieved at oesophagectomy were examined retrospectively by two pathologists for evidence of a response to chemotherapy. Patients were classified as lymph node‐negative (either negative nodes with no evidence of previous tumour involvement or negative with evidence of complete regression) or positive (allocated a lymph node regression score based on the proportion of fibrosis to residual tumour). Lymph node responders (score 1, complete response; 2, less than 10 per cent remaining tumour; 3, 10–50 per cent remaining tumour) and non‐responders (score 4, more than 50 per cent viable tumour; 5, no response) were compared in survival analyses using Kaplan–Meier and Cox regression analysis.
Among 377 patients, 256 had neoadjuvant chemotherapy. Overall, 68 of 256 patients (26·6 per cent) had a lymph node response and 115 (44·9 per cent) did not. The remaining 73 patients (28·5 per cent) had negative lymph nodes with no evidence of regression. Some patients had a lymph node response in the absence of a response in the primary tumour (27 of 99, 27 per cent). Lymph node responders had a significant survival benefit (P < 0·001), even when stratified by patients with or without a response in the primary tumour. On multivariable analysis, lymph node responders had decreased overall (hazard ratio 0·53, 95 per cent c.i. 0·36 to 0·78) and disease‐specific (HR 0·42, 0·27 to 0·66) mortality, and experienced reduced local and systemic recurrence.
Lymph node regression is a strong prognostic factor and may be more important than response in the primary tumour.Full text
You may also be interested in
Meta‐analysis of risk factors and complications associated with atrial fibrillation after oesophagectomy. BJS 2019; 106: 534-547.
Authors: D. Schizas, M. Kosmopoulos, S. Giannopoulos, S. Giannopoulos, D. G. Kokkinidis, N. Karampetsou et al.
Changes in gut hormones, glycaemic response and symptoms after oesophagectomy. BJS 2019; 106: 735-746.
Authors: J. A. Elliott, N. G. Docherty, C. F. Murphy, H.‐G. Eckhardt, S. L. Doyle, E. M. Guinan et al.
Diagnostic performance of MRI for assessment of response to neoadjuvant chemoradiotherapy in oesophageal cancer. BJS 2019; 106: 596-605.
Authors: S. E. Vollenbrock, F. E. M. Voncken, J. M. van Dieren, D. M. J. Lambregts, M. Maas, G. J. Meijer et al.
Major hepatectomy with or without pancreatoduodenectomy for advanced gallbladder cancer. BJS 2019; 106: 626-635.
Authors: T. Mizuno, T. Ebata, Y. Yokoyama, T. Igami, J. Yamaguchi, S. Onoe et al.
Meta‐analysis of clinical outcome after treatment for achalasia based on manometric subtypes. BJS 2019; 106: 332-341.
Authors: C. Andolfi, P. M. Fisichella
Systematic review of management of incidental gallbladder cancer after cholecystectomy. BJS 2019; 106: 32-45.
Authors: K. Søreide, R. V. Guest, E. M. Harrison, T. J. Kendall, O. J. Garden, S. J. Wigmore et al.
Relationship between R1 resection, tumour rupture and recurrence in resected gastrointestinal stromal tumour. BJS 2019; 106: 419-426.
Authors: T. Hølmebakk, B. Bjerkehagen, I. Hompland, S. Stoldt, K. Boye
Notes: Tumour rupture is most important
Survival after neoadjuvant chemoradiotherapy and oesophagectomy versus definitive chemoradiotherapy for patients with oesophageal squamous cell carcinoma. BJS 2019; 106: 255-262.
Authors: B.‐Y. Wang, S.‐C. Wu, H.‐C. Chen, W.‐H. Hung, C.‐H. Lin, C.‐L. Huang et al.
Notes: Surgery after chemoradiation indicated
Effect of preoperative biliary drainage on cholestasis‐associated inflammatory and fibrotic gene signatures in perihilar cholangiocarcinoma. BJS 2019; 106: 55-58.
Authors: M. J. Reiniers, L. de Haan, R. Weijer, J. K. Wiggers, A. Jongejan, P. D. Moerland et al.
Impact of postoperative complications on outcomes after oesophagectomy for cancer. BJS 2019; 106: 111-119.
Authors: L. Goense, J. Meziani, J. P. Ruurda, R. van Hillegersberg
Meta‐analysis of the influence of lifestyle changes for preoperative weight loss on surgical outcomes. BJS 2019; 106: 181-189.
Authors: M. Roman, A. Monaghan, G. F. Serraino, D. Miller, S. Pathak, F. Lai et al.
Notes: Possible but how much is enough?
Multicentre cohort study of antihypertensive and lipid‐lowering therapy cessation after bariatric surgery. BJS 2019; 106: 286-295.
Authors: J. Thereaux, T. Lesuffleur, S. Czernichow, A. Basdevant, S. Msika, D. Nocca et al.
Notes: Better than controls